PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
5 hedge funds and large institutions have $9.9M invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 3 closing their positions.
38% less funds holding
Funds holding: 8 → 5 (-3)
56% less capital invested
Capital invested by funds: $22.7M → $9.9M (-$12.8M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$9.31M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$590K |
| 3 |
Millennium Management
New York
|
-$78.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BI
1
BVF Inc
San Francisco,
California
| $4.23M | – | – | – |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $4.23M | – | – | – |
|
|
SFM
3
Sphera Funds Management
Tel Aviv,
Israel
| $796K | – | – | – |
|
|
DG
4
Delek Group
Herzliya,
Israel
| $487K | – | – | – |
|
|
5
Millennium Management
New York
| $157K | -$78.3K | -1,057 | -31% |
|
|
BBA
6
Baker Bros. Advisors
New York
| – | -$9.31M | -108,597 | Closed |
|
|
EC
7
EcoR1 Capital
San Francisco,
California
| – | -$590K | -6,957 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$11K | -125 | Closed |
|
PHXM Hedge Fund Activity: Q4 2018 in Review
5 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q4 2018, worth a combined $9.9M — down 56% from $22.7M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PHXM and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $9.31M sold.
- 5 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q4 2018, down from 8 in Q3 2018.
- Funds reported $9.9M of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q4 2018, down 56% quarter-over-quarter.
- 0 funds opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q4 2018 and 3 closed out, a net change of -3 holders.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q4 2018 was Baker Bros. Advisors, an estimated $9.31M sold.
Based on aggregated 13F filings for Q4 2018.